Efficacy of recombinant Bacillus Calmette-Guérin containing dltA in <i>in vivo</i> three-dimensional bio-printed bladder cancer-on-a-chip and <i>ex vivo</i> orthotopic mouse model-Reference-Cited by-同舟云学术

Efficacy of recombinant Bacillus Calmette-Guérin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model

Published:2023 Issue:3 Volume:64 Page:296
ISSN:2466-0493
Container-title:Investigative and Clinical Urology
language:en
Short-container-title:Investig Clin Urol

Author:

Choi Joongwon¹^ORCID,Jung Tae Young²^ORCID,Kim Jung Hoon¹^ORCID,Maeng Sejung³^ORCID,Kang Su Jeong³^ORCID,Kim Mirinae³^ORCID,Choi Young Wook³^ORCID,Choi Se Young³^ORCID,Kim Sung-Hwan⁴^ORCID,Chang In Ho³^ORCID

Affiliation:

1. Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.

2. Department of Urology, VHS Medical Center, Seoul, Korea.

3. Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

4. Cellsmith Inc., Seoul, Korea.

Funder

National Research Foundation of Korea

VHS Medical Center

Publisher

XMLink

Subject

Urology

Link

https://icurology.org/pdf/10.4111/icu.20220293

Reference30 articles.

1. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

2. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

3. Intravesical Pharmacotherapy for Non–Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results

4. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update